Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rezpegaldesleukin in atopic dermatitis
NCT04081350Phase 1Completed
- Sponsor
- Nektar Therapeutics
- Start
- Dec 2019
- Primary completion
- Jun 2022
- Modality
- Biologic, rProtein (Recombinant Protein), Polyethylene glycol conjugate
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of rezpegaldesleukin in atopic dermatitis (AD) (4 arms), sponsored by Nektar Therapeutics. Primary endpoint: Number of Participants with One or More Serious Adverse Event(s) Considered by the Investigator to be Related to Study Drug Administration at Week 48. Started Dec 2019; status: completed.
02
Drugs
rezpegaldesleukin
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT04081350.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04081350.